07:00 , Sep 12, 2016 |  BC Week In Review  |  Clinical News

Viaskin rPT: Phase I started

DBV began a double-blind, placebo-controlled, dose-escalation, Swiss Phase I trial to evaluate two 48-hour applications of 25 and 50 ug Viaskin rPT given 2 weeks apart in about 60 healthy adults. Subjects will receive 1...
07:00 , Jul 18, 2011 |  BC Week In Review  |  Clinical News

Boostrix regulatory update

FDA approved an sBLA for GlaxoSmithKline's Boostrix to prevent tetanus, diphtheria and pertussis in subjects ages >=65 years. The tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) booster vaccine is already approved in the...
07:00 , Apr 5, 2010 |  BC Week In Review  |  Company News

GlaxoSmithKline sales and marketing update

GlaxoSmithKline will provide free adult vaccines to U.S. patients who lack vaccine coverage and whose incomes are no more than 250% of the federal poverty level, or $27,075 for a single person. The GSK Vaccines...
01:26 , Mar 30, 2010 |  BC Extra  |  Company News

GSK begins vaccine access program

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) launched its GSK Vaccines Access Program to provide free vaccines to low income adults in the U.S. who do not have insurance coverage. The program includes GSK's Cervarix against HPV for...
23:58 , Aug 29, 2008 |  BC Extra  |  Politics & Policy

CDC releases pre-teen vaccine PSAs

The U.S. Centers for Disease Control and Prevention's National Center for Immunization and Respiratory Disease released new public service announcements to encourage pre-teen vaccinations. The PSAs target the parents of 11- and 12-year-olds and recommend...
07:00 , Aug 20, 2007 |  BioCentury  |  Regulation

Watchdog rebuffed on Gardasil

The not-for-profit National Vaccine Information Center called for a warning about Gardasil based on an analysis released last week suggesting the HPV vaccine is associated with an increased risk of serious adverse events when given...
07:00 , Oct 24, 2005 |  BC Week In Review  |  Clinical News

Boostrix infectious data

In a double-blind, Havrix-controlled U.S. trial in 2,781 healthy volunteers, Boostrix was 92% effective in protecting at-risk adolescents and adults. Boostrix led to 1 confirmed case of pertussis vs. 9 with control. GSK markets ...
01:31 , Jun 11, 2005 |  BC Extra  |  Company News

FDA approves Adacel vaccine

FDA approved Adacel combination booster vaccine from sanofi-aventis (Euronext:SAN; SNY) for use in adolescents and adults ages 11-64. The diphtheria, tetanus and acellular pertussis (DtaP) vaccine, along with Boostrix from GlaxoSmithKline (LSE:GSK; GSK), were unanimously...
07:00 , May 9, 2005 |  BC Week In Review  |  Clinical News

Boostrix regulatory update

FDA approved a BLA for Boostrix, a tetanus toxoid, reduced diphtheria toxoid and acellular pertussis booster vaccine, to treat bacterial infetions in individuals aged 10 to 18. GlaxoSmithKline plc (LSE:GSK; GSK), London, U.K.   Product: ...
08:00 , Mar 21, 2005 |  BC Week In Review  |  Clinical News

Boostrix regulatory update

FDA's Vaccines and Related Biological Products Advisory Committee unanimously recommended approval for Boostrix tetanus toxoid, reduced diphtheria toxoid and acellular pertussis booster vaccine for children ages 10-18. GlaxoSmithKline plc (LSE:GSK; GSK), London, U.K.   Product: ...